EUCTR2004-000860-28-IT进行中（未招募）不适用
Phase III, Open-Label, Randomized, Multicenter Efficacy and Safety Study of Bendamustine Hydrochloride Versus Chlorambucil in Treatment-Nave Patients with (Binet Stage B/C) B-CLL Requiring Therapy
RIBOSEPHARM0 个研究点开始时间: 2005年3月16日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX)Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)MedDRA version: 23.0Level: PTClassification code: 10071977Term: Anaplastic lymphoma kinase gene mutation Class: 100000004850CTIS2023-506859-13-00F. Hoffmann-La Roche AG325
进行中（未招募）
不适用
Ceftazidime-Avibactam for the treatment of infections due to Ceftazidime Resistant PathogenscUTI, Complicated Urinary Tract Infection, cIAI, Complicated intra-abdominal infectionEUCTR2012-000726-21-DEAstraZeneca AB400
进行中（未招募）
1 期
Ceftazidime-Avibactam for the treatment of infections due to Ceftazidime Resistant PathogensEUCTR2012-000726-21-CZAstraZeneca AB400
进行中（未招募）
不适用
Ceftazidime-Avibactam for the treatment of infections due to Ceftazidime Resistant PathogensEUCTR2012-000726-21-BGAstraZeneca AB400
进行中（未招募）
1 期
Ceftazidime-Avibactam for the treatment of infections due to Ceftazidime Resistant PathogenscUTI, Complicated Urinary Tract Infection, cIAI, Complicated intra-abdominal infectionMedDRA version: 14.1Level: LLTClassification code 10046574Term: Urinary tract infection NOSSystem Organ Class: 100000004862MedDRA version: 14.1Level: LLTClassification code 10056570Term: Intra-abdominal infectionSystem Organ Class: 100000004862EUCTR2012-000726-21-ITAstraZeneca AB400